Moleculin Biotech Inc. (MBRX)
Company Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses.
Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.
The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies.
It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19.
The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
| Country | United States |
| IPO Date | Jun 2, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Walter V. Klemp |
Contact Details
Address: 5300 Memorial Drive Houston, Texas United States | |
| Website | https://www.moleculin.com |
Stock Details
| Ticker Symbol | MBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659617 |
| CUSIP Number | 60855D200 |
| ISIN Number | US60855D2009 |
| Employer ID | 47-4671999 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Walter V. Klemp | Co-Founder, Chairman, President & Chief Executive Officer |
| Jonathan P. Foster CPA | Executive Vice President & Chief Financial Officer |
| Dr. Donald H. Picker Ph.D. | Chief Scientific Officer |
| Dr. John Paul Waymack M.D., Sc.D. | Senior Chief Medical Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer of New Products |
| Dr. Waldemar Priebe Ph.D. | Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board |
| Dr. Wolfram C. M. Dempke M.B.A., M.D., Ph.D. | European Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 03, 2025 | PRE 14A | Filing |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 424B5 | Filing |
| Feb 24, 2025 | RW | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 11, 2025 | 8-K | Current Report |
| Feb 11, 2025 | S-1/A | [Amend] Filing |
| Feb 10, 2025 | 8-K | Current Report |